Drugs / F-18 Fluoroethyltyrosine (FET)
F-18 Fluoroethyltyrosine (FET)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04044937 | Oct 2018 → Mar 2024 | brain neoplasm, glioblastoma, grade II glioma, grade III glioma | Thomas Hope | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-18 Fluoroethyltyrosine (FET) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04044937 ↗ |
| Modality | Diagnostic / imaging agent | “Imaging agents such as FET can help oncologist to see the tumor better during a positron emission tomography (PET) scan.” NCT04044937 ↗ |
| Route | Intravenous | “Participants receive F-18 fluoroethyltyrosine intravenously (IV) over approximately 1 minute” NCT04044937 ↗ |